Effects of Telemonitoring in Quality of Life Amongst Cancer Patients

Last updated: April 5, 2024
Sponsor: Universidad Nacional Andres Bello
Overall Status: Active - Recruiting

Phase

N/A

Condition

Cancer

Treatment

Contigo Application

Clinical Study ID

NCT06086990
UNAB-005
  • Ages > 18
  • All Genders

Study Summary

This interventional study aims to explore the potential of a smartphone app, Contigo, in enhancing the quality of life for patients with various cancers compared to standard care. The investigators will asses effects on quality of life, depressive symptoms, and appointment adherence.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Adult patients (>18 years old).
  • Recent histologically confirmed diagnosis (within the last 3 months) of bronchogenic,breast, gallbladder, gastric, colorectal, or prostate cancer in any of its forms.
  • Awaiting initiation of curative intent treatment for the disease using any modality (radiation therapy, chemotherapy, immunotherapy, etc.) at the UC-Christus CancerCenter.
  • Possession of a smartphone, regardless of its native operating system (iOS® orAndroid®).
  • Willingness to sign an informed consent form to participate in the study.

Exclusion

Exclusion Criteria:

  • Any form of sensory impairment preventing app usage.
  • Cognitive impairment.
  • Psychiatric pathology hindering app usage.
  • Unwillingness to participate in the study.
  • Concurrent participation in another clinical trial addressing healthcare technologies.

Study Design

Total Participants: 80
Treatment Group(s): 1
Primary Treatment: Contigo Application
Phase:
Study Start date:
April 01, 2024
Estimated Completion Date:
March 31, 2025

Study Description

The primary objective of this study is to determine if utilizing a smartphone app for disease monitoring improves the self-reported quality of life using validated questionnaires in patients with diverse solid cancers compared to standard care. Secondary objectives focused on evaluating its impact on depressive symptoms and assessing adherence to in-person appointments. This study involves a randomized trial among patients recently diagnosed with specific forms of cancer and undergoing curative treatment at the UC Christus Cancer Center. The eligible participants, 80 adults with recent histologically confirmed cancer diagnoses, will be randomized to receive either the smartphone application (Contigo) or standard educational care. Randomization will be performed independently using an allocation sequence that will be kept concealed from clinical investigators. Contigo offers two primary functions: monitoring cancer patients and delivering educational content to aid patients in dealing with common clinical situations related to their disease. The study will assess outcomes such as quality of life changes, depressive symptom development, and adherence to in-person appointments. All analyses will be undertaken under the intention to treat principle by a statistician unaware of treatment allocation.

Connect with a study center

  • UC Christus Cancer Centre

    Santiago,
    Chile

    Active - Recruiting

Map preview placeholder

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.